Prognostic Impact of 18-F-Florbetaben Amyloid PET Imaging in Patients with Isolated Increases in Cerebrospinal Fluid Phospho-Tau Biomarkers: A Longitudinal Study.

Fiche publication

Date publication

mars 2021

Journal

Journal of Alzheimer's disease : JAD

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine

Tous les auteurs :
Jardel A, Hopes L, Malaplate C, Roch V, Manca C, Rivasseau Jonveaux T, Verger A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33682716

Résumé

This longitudinal study evaluates the prognostic impact of amyloid PET in patients suspected of Alzheimer's disease and presenting with isolated cerebrospinal fluid (CSF) increases in P-Tau proteins (NCT02556502). The rate of conversion, based on the DSM-5 criteria and all collected data (average follow-up of 39.2±13.2 months), was determined by a panel of experts blinded to the PET results and was 75%(6/8) for positive and 35%(6/17) for negative baseline amyloid PET. In this population with isolated CSF increases in P-Tau, a positive baseline amyloid PET was associated with greater than twice the proportion of dementia conversions within the following three years.